GRAIL (NASDAQ:GRAL) Stock Price Down 4.2% - Should You Sell?

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) traded down 4.2% during trading on Friday . The company traded as low as $47.58 and last traded at $47.29. 471,147 shares changed hands during trading, a decline of 61% from the average session volume of 1,208,363 shares. The stock had previously closed at $49.38.

Analyst Upgrades and Downgrades

GRAL has been the subject of a number of recent analyst reports. Morgan Stanley raised their price target on shares of GRAIL from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, March 18th. Canaccord Genuity Group upped their price objective on shares of GRAIL from $32.00 to $43.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th.

GRAIL Stock Performance

The company has a market capitalization of $1.85 billion and a PE ratio of -0.84. The company has a 50 day moving average price of $39.25 and a 200 day moving average price of $31.96.

GRAIL (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($3.10) EPS for the quarter, beating analysts' consensus estimates of ($4.03) by $0.93. The firm had revenue of $31.84 million for the quarter, compared to the consensus estimate of $35.80 million. GRAIL had a negative net margin of 1,464.53% and a negative return on equity of 17.99%. On average, equities analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Insider Transactions at GRAIL

In other GRAIL news, CEO Robert P. Ragusa sold 94,035 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total transaction of $3,190,607.55. Following the transaction, the chief executive officer owned 734,627 shares of the company's stock, valued at $24,925,894.11. This trade represents a 11.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Joshua J. Ofman sold 48,213 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $33.93, for a total value of $1,635,867.09. Following the completion of the sale, the president owned 511,460 shares of the company's stock, valued at $17,353,837.80. This trade represents a 8.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 183,398 shares of company stock valued at $6,222,694.

Hedge Funds Weigh In On GRAIL

Several large investors have recently added to or reduced their stakes in GRAL. Crcm LP bought a new stake in GRAIL during the fourth quarter valued at $65,061,000. Sessa Capital IM L.P. bought a new stake in shares of GRAIL during the 4th quarter valued at about $53,550,000. Primecap Management Co. CA bought a new stake in shares of GRAIL during the 4th quarter valued at about $37,118,000. Baker BROS. Advisors LP acquired a new stake in GRAIL during the fourth quarter worth about $29,098,000. Finally, Vanguard Group Inc. bought a new position in GRAIL in the fourth quarter worth about $25,902,000.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.